2005 Antivirals Pipeline 
| Phase of Development | NRTI
|
NNRTI
|
PI
|
EI*
|
Integrase Inhibitors
|
Maturation Inhibitors
|
Other
|
| Preclinical | BPH-218, bisphosphonate NRTI, U Pittsburgh | TMC-278, Diarylpyrimidine (DAPY), Tibotec | VX-385, GSK/Vertex | Benzothiepine and Benzazepine derivatives, CCR5 antagonists, Takeda | L-870812, MSD | enJS56A1, Escape Inhibitor, U Georgia | RWJ67567, p38 inhibitor, U Penn / J&J |
| Dinucleoside polyphosphates, NRTI "potentiators", U Miami | NVP C-8 derivatives, BI | AG-1859, Pfizer | Betulinic Acid Derivatives (BAD), U North Carolina | Carbazole derivative, NIID, Japan | Chloroquine, Catholic U, Rome | ACH-CIP, capsid inhibitor, Achillion | |
| siRNA molecule, CombiMatrix | Tricyclic NNRTI, BMS | KRH-2731, X4 antagonist, Kureha | 810871, GSK | Betulinic Acid Derivatives (BAD), U North Carolina | α TRIM5, capsid inhibitor, Dana Farber, NIAID | ||
| SMP-717, Advanced Life Sciences | PRO-140, monoclonal antibody (MAb), Progenics | Styrylquinoline, Bioalliance Pharma | CDK inhibitor, Gilead | ||||
| SMP-610, Advanced Life Sciences | GBV-C, virus that increases chemokines including RANTES (CCR5 blocker), U Iowa | V-165, Rega Institute, Belgium | Mifepristone, glucocorticoid antagonist, U Pittsburgh | ||||
| 695634, GSK | 15K & 15D, co-receptor docking inhibitors, NCI | Mycelium integrasone, Fungal polyketide, MSD | RSC-1838, GSK/Shionogi | ||||
| S-DABO derivatives (HIV-1 and -2), Fudan U, China | RC-112 & Retrocyclin-1, theta-Defensins, DASTLR | Indolicidin, NIH | siRNA molecule, Nef inhibitor, CombiMatrix | ||||
| Oligodeoxynucleotides, U Hospital, Zurich | ONO-4128, CCR5 antagonist, GSK/ONO | Beta-diketo acids, U Parma/Sassari, Italy | Resveretol, Egr1 gene activator, NCI | ||||
| PL-100, Procyon BioPharma | D5, artificial MAb, MSD | MDI-P, electrolyzed free radical, Medical Discoveries | |||||
| IC9564, Duke University | Poly (acrylic) acid, Chinese Academy of Science | ||||||
| 004, CCR5 mAB, Human Genome Sciences | |||||||
| MDX-010, multi-receptor MAb, Medarex | |||||||
| UMIST, Genetic Innovation Network | |||||||
| NB-2 and NB-64, gp41 coiled coil blocker, Shibo & Kumar | |||||||
| Phase I | SPD-754, Shire Biochem | AMD-070, CXCR4 antagonist, Anormed | HGTV43, gene regulation/editing inhibitor, Enzo | ||||
| AMD-887, CCR5 antagonist, Anormed | VRX496 lentiviral vector VIRxSYS Corp |
||||||
| CCR5 antagonist, GSK-873140, GSK | BAY 50-4798, IL2 selective agonist, Bayer | ||||||
| Phase I/II or Phase IB | MIV-210 (FGV), Medivir/GSK | BMS-043, anti-gp120 blocker, BMS | PA-457, Budding inhibitor, Panacos | ||||
| Reverset (D-D4FC), Pharmasset/Incyte | SCH D, CCR5 antagonist, Schering Plough | ||||||
| SN-1212/1461, mutagenic deoxyribonucleoside, Koronis | SP-01A, Entry Inhibitor, Samaritan Pharma | ||||||
| Racivir (PSI 5004), Pharmasett | TNX-355, Anti-CD4 MAb, Tanox/Biogen | ||||||
| Phase II | Elvucitabine (ACH-126), Achillion | Calanolide A, Advanced Life Sciences | TMC-114/r, Tibotec/J&J | PRO-542, attachment inhibitor, Progenics | |||
| Amdoxovir (DAPD), Emory University | TMC-125 (etravirine), Tibotec/J&J | UK-427,857, CCR5 antagonist, Pfizer | |||||
| Alovudine (MIV-310), Medivir/BI | |||||||
| Phase III | Capravirine/r, Pfizer/Agouron | Tipranavir/r, Boehringer Ingelheim | |||||
| Notes: EI = entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry. possibly on hold Recent news from the XIth Conference on Retroviruses and Opportunistic Infections, San Francisco, 8-11 February, 2004 |
|||||||
HIV Treatment IndexTAG index